-
2024-510810-33-00
5
2024-10-14
Severe eosinophilic asthma
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2025-522983-33-00
5
Chronic rhinosinusitis with nasal polyps
-
2025-523871-44-00
5
Cutaneous Manifestations of Lupus Erythematosus With or Without System
-
2025-524316-11-00
5
2026-06-11
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-521950-41-00
5
2026-06-05
severe uncontrolled asthma
-
2024-519994-20-00
5
2026-06-01
Agitation Associated with Alzheimer’s Disease
-
2025-523180-38-00
4
2026-05-12
Uncontrolled Moderate to Severe Eosinophilic Asthma
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2024-518840-18-00
5
2025-12-10
Varicella
-
2025-521216-19-00
5
2025-12-10
Schizophrenia
-
2024-520195-94-00
5
2025-09-25
BP-I mania or mania with mixed features
-
2024-515853-48-00
5
2025-09-05
advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-501354-10-01
5
2023-06-21
axial spondyloarthritis
-
2022-500257-16-00
5
2023-03-17
Diabetic Foot Infections
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-523659-73-00
5
2026-05-11
Obesity